CN104043135B - 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 - Google Patents
一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN104043135B CN104043135B CN201410265653.2A CN201410265653A CN104043135B CN 104043135 B CN104043135 B CN 104043135B CN 201410265653 A CN201410265653 A CN 201410265653A CN 104043135 B CN104043135 B CN 104043135B
- Authority
- CN
- China
- Prior art keywords
- paclitaxel
- indocyanine green
- hsa
- albumin
- icg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960001592 paclitaxel Drugs 0.000 title claims abstract description 155
- 229930012538 Paclitaxel Natural products 0.000 title claims abstract description 153
- 229960004657 indocyanine green Drugs 0.000 title claims abstract description 134
- 102000009027 Albumins Human genes 0.000 title claims abstract description 78
- 108010088751 Albumins Proteins 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- -1 indocyanine green paclitaxel compound Chemical class 0.000 title claims abstract description 15
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 142
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims abstract description 122
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 56
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 56
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 57
- 239000000243 solution Substances 0.000 claims description 36
- 239000008055 phosphate buffer solution Substances 0.000 claims description 18
- 239000002105 nanoparticle Substances 0.000 claims description 16
- 238000011068 loading method Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 23
- 239000000463 material Substances 0.000 abstract description 20
- 238000007626 photothermal therapy Methods 0.000 abstract description 11
- 238000002512 chemotherapy Methods 0.000 abstract description 8
- 238000000799 fluorescence microscopy Methods 0.000 abstract description 8
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 36
- 230000000694 effects Effects 0.000 description 19
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000003917 TEM image Methods 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 208000005598 Angioid Streaks Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 208000033825 Chorioretinal atrophy Diseases 0.000 description 1
- 208000016623 Choroid neoplasm Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000004224 UV/Vis absorption spectrophotometry Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000002588 choroid cancer Diseases 0.000 description 1
- 101150016491 chsA gene Proteins 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
HSA | 人血清白蛋白 |
ICG | 吲哚菁绿 |
PTX | 紫杉醇 |
HSA-ICG | 白蛋白吲哚菁绿复合物 |
HSA-PTX | 白蛋白紫杉醇复合物 |
HSA-ICG-PTX | 白蛋白吲哚菁绿紫杉醇复合物 |
PBS | 磷酸盐缓冲液 |
Claims (9)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410265653.2A CN104043135B (zh) | 2014-06-13 | 2014-06-13 | 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 |
CA2951729A CA2951729C (en) | 2014-06-13 | 2014-10-28 | Albumin-indocyanine green-paclitaxel complex and preparation method and use thereof |
PCT/CN2014/089650 WO2015188570A1 (zh) | 2014-06-13 | 2014-10-28 | 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410265653.2A CN104043135B (zh) | 2014-06-13 | 2014-06-13 | 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104043135A CN104043135A (zh) | 2014-09-17 |
CN104043135B true CN104043135B (zh) | 2017-05-24 |
Family
ID=51496850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410265653.2A Active CN104043135B (zh) | 2014-06-13 | 2014-06-13 | 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN104043135B (zh) |
CA (1) | CA2951729C (zh) |
WO (1) | WO2015188570A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104043135B (zh) * | 2014-06-13 | 2017-05-24 | 苏州大学 | 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 |
CN105267965B (zh) * | 2015-10-15 | 2018-08-21 | 苏州杰纳生物科技有限公司 | 一种聚(乳酸-羟基乙酸)复合物及其制备方法 |
CN106932496A (zh) * | 2015-12-30 | 2017-07-07 | 辽宁药联制药有限公司 | 一种用高效液相色谱法测定吲哚菁绿有关物质的方法 |
CN106267228B (zh) * | 2016-08-15 | 2019-08-23 | 苏州大学 | 一种共装载化疗药物和放疗药物的蛋白及其应用 |
CN106166141A (zh) * | 2016-09-11 | 2016-11-30 | 复旦大学 | 一种用于肿瘤成像与治疗的多功能复合纳米药物及其制备方法 |
CN106333941B (zh) * | 2016-10-24 | 2019-12-13 | 聊城大学 | 一种紫杉醇白蛋白复合物的制备工艺 |
CN106902351A (zh) * | 2017-02-24 | 2017-06-30 | 北京大学 | 吲哚菁绿j聚集体的制备方法及应用 |
CN108771659B (zh) * | 2018-07-05 | 2021-05-04 | 天津大学 | 一种吲哚箐绿荧光示踪的反式茴香脑-白蛋白纳米颗粒的制备方法 |
CN108853498B (zh) * | 2018-07-05 | 2021-03-23 | 华侨大学 | 一种吲哚菁绿聚合物纳米颗粒的制备方法及其应用 |
CN110251672B (zh) * | 2019-06-18 | 2022-04-01 | 深圳大学 | 一种纳米诊疗剂及其制备方法与应用 |
CN111388451B (zh) * | 2020-04-29 | 2023-05-23 | 南京工业大学 | 蛋白自组装铁基纳米粒及其制备方法与抗肿瘤药物递送系统中的应用 |
CN112546221B (zh) * | 2020-12-11 | 2023-12-19 | 深圳先进技术研究院 | 一种肿瘤诊疗药物及其制备方法和应用 |
WO2023039691A1 (zh) * | 2021-09-17 | 2023-03-23 | 苏州大学 | 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用 |
CN113730608A (zh) * | 2021-10-11 | 2021-12-03 | 南京诺源医疗器械有限公司 | 注射用荧光示踪剂及其制备方法 |
CN114652848A (zh) * | 2022-03-18 | 2022-06-24 | 山东大学齐鲁医院 | 一种peg化人血清白蛋白纳米材料及其制备方法和在肿瘤诊疗中的应用 |
CN115350277B (zh) * | 2022-09-16 | 2023-08-25 | 中国医学科学院生物医学工程研究所 | 一种基于shp2抑制剂和光敏剂的白蛋白纳米药物及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011017835A1 (en) * | 2009-08-11 | 2011-02-17 | Nanjing University | Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding |
US9731012B2 (en) * | 2012-03-30 | 2017-08-15 | President And Fellows Of Harvard College | Laser-actuated therapeutic nanoparticles |
CN102988996A (zh) * | 2012-12-19 | 2013-03-27 | 清华大学 | 一种制备稳定的白蛋白纳米颗粒的方法 |
CN103495179A (zh) * | 2013-09-27 | 2014-01-08 | 深圳先进技术研究院 | 一种多聚体白蛋白纳米球及其制备方法和应用 |
CN104043135B (zh) * | 2014-06-13 | 2017-05-24 | 苏州大学 | 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 |
-
2014
- 2014-06-13 CN CN201410265653.2A patent/CN104043135B/zh active Active
- 2014-10-28 WO PCT/CN2014/089650 patent/WO2015188570A1/zh active Application Filing
- 2014-10-28 CA CA2951729A patent/CA2951729C/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2951729C (en) | 2019-02-12 |
CA2951729A1 (en) | 2015-12-17 |
CN104043135A (zh) | 2014-09-17 |
WO2015188570A1 (zh) | 2015-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104043135B (zh) | 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 | |
Lei et al. | Polydopamine-coated mesoporous silica nanoparticles for multi-responsive drug delivery and combined chemo-photothermal therapy | |
Liu et al. | Functionalized poly (pyrrole-3-carboxylic acid) nanoneedles for dual-imaging guided PDT/PTT combination therapy | |
Liu et al. | Combined photothermal and photodynamic therapy delivered by PEGylated MoS 2 nanosheets | |
Yu et al. | Tumor microenvironment-triggered fabrication of gold nanomachines for tumor-specific photoacoustic imaging and photothermal therapy | |
Cao et al. | Pt@ polydopamine nanoparticles as nanozymes for enhanced photodynamic and photothermal therapy | |
Zhang et al. | Near-infrared-triggered in situ hybrid hydrogel system for synergistic cancer therapy | |
Liu et al. | In vitro photothermal study of gold nanoshells functionalized with small targeting peptides to liver cancer cells | |
KR102081666B1 (ko) | 암 치료용 약학 조성물 | |
Tian et al. | Dye-loaded mesoporous polydopamine nanoparticles for multimodal tumor theranostics with enhanced immunogenic cell death | |
CN106139144A (zh) | 一种具有协同抗肿瘤特性的透明质酸修饰的金‑碳纳米球及其制备方法与应用 | |
Du et al. | NIR-activated multi-hit therapeutic Ag2S quantum dot-based hydrogel for healing of bacteria-infected wounds | |
CN106729738A (zh) | 一种枝状金铂双金属纳米粒子及其制备方法和应用 | |
CN106519213A (zh) | 一种铂基化氟硼二吡咯类化合物及制备方法和应用 | |
Jin et al. | A multifunctional hydrogel containing gold nanorods and methylene blue for synergistic cancer phototherapy | |
Xia et al. | Enhanced photodynamic therapy through supramolecular photosensitizers with an adamantyl-functionalized porphyrin and a cyclodextrin dimer | |
CN110063933A (zh) | 一种葡聚糖基纳米凝胶及其制备方法和应用 | |
Wen et al. | Nitrogen-doped carbon dots/curcumin nanocomposite for combined Photodynamic/photothermal dual-mode antibacterial therapy | |
CN105106958A (zh) | 具有近红外光热效应的铜基人血白蛋白纳米复合物及其制备方法和应用 | |
Zhang et al. | A multi-functional nanoplatform for tumor synergistic phototherapy | |
WO2021083370A1 (zh) | 一种特异性激活免疫系统的纳米材料的制备和应用 | |
Chu et al. | Manganese amplifies photoinduced ROS in toluidine blue carbon dots to boost MRI guided chemo/photodynamic therapy | |
Ouyang et al. | Efficient improvement in chemo/photothermal synergistic therapy against lung cancer using Bi@ Au nano-acanthospheres | |
Tian et al. | Porphyrin-based porous organic polymer coated ZIF-8 nanoparticles as tumor targeted photosensitizer for combination cancer photodynamic/photothermal therapy | |
Wang et al. | Hypocrellin Derivative‐Loaded Calcium Phosphate Nanorods as NIR Light‐Triggered Phototheranostic Agents with Enhanced Tumor Accumulation for Cancer Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Qian Inventor after: Liu Zhuang Inventor before: Liu Zhuang Inventor before: Chen Qian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LIU ZHUANG CHEN QIAN TO: CHEN QIAN LIU ZHUANG |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201105 Address after: Unit 102-1, building A4, 218 Xinghu street, Suzhou Industrial Park, Suzhou area, China (Jiangsu) pilot Free Trade Zone, Suzhou City, Jiangsu Province Patentee after: Suzhou Baimai biomedical Co.,Ltd. Address before: 215123 No. 199 benevolence Road, Suzhou Industrial Park, Jiangsu, China Patentee before: Suzhou University |
|
TR01 | Transfer of patent right |